viracta.com (VIRX) Price-to-Projected Revenue Ratio
The forward P/S trajectory demonstrates the potential of the precision activator IT platform against lymphomas, where is the current level of the metric for Viracta Therapeutics (VIRX). Business efficiency relies on the "Kick and Kill" method for the targeted destruction of tumors associated with the Epstein-Barr virus. A stable staff of epigenetics experts and the hiring of data analysts guarantee the achievement of key clinical goals.
Analytical breakdowns for Viracta Therapeutics, Inc. (VIRX)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Equity Ratio Viracta Therapeutics|VIRX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Viracta Therapeutics Inc.|VIRX - Company Aggregate Debts|Debt to Book Value Viracta Therapeutics Inc.|VIRX - Company Long-Term Loans and Borrowings|Company Current Liabilities Viracta Therapeutics|Quick Ratio viracta.com
- financial results and valuation multiples details:
VIRX - Final Profit|Projected Future Earnings Viracta Therapeutics|VIRX - Market Cap to Earnings|Future Price to Earnings Viracta Therapeutics|VIRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Viracta Therapeutics|VIRX - Operating profit EBITDA|Earnings per share for the last twelve months Viracta Therapeutics|VIRX - Earnings per one share for the last 12 months|Quarterly EPS earnings growth viracta.com|VIRX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Viracta Therapeutics
- total revenue and sales volume data:
Fundamental company analysis:Viracta Therapeutics, Inc. (VIRX)
For Viracta Therapeutics (VIRX), which is developing an innovative "kick and kill" strategy in cancer therapy, the forward P/S ratio reflects market expectations for the future commercialization of its drugs. This metric correlates current market capitalization with projected revenue per share, allowing investors to assess the premium paid for potential growth and timely revise capital concentration risks when the indicator reaches extreme values.
Key competitors
Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Renovaro - Forward P/S Multiple|Mural Oncology (MURA) - Forward Price-to-Revenue Multiple|KAPA: Forward P/S Multiple|OKUR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CytoMed Therapeutics Limited|CRIS: Forward Price to Sales|Forward P/S Multiple APLM|Forward P/S Multiple tharimmune.com (THAR)|Advanced Biomed Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales GNPX|Calidi Biotherapeutics, Inc. - Forward P/S Multiple|Sunshine Biopharma (SBFM) - Forward Price-to-Revenue Multiple|XBIO: Forward P/S Multiple|SLRX - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PPBT|Forward P/S Multiple American Oncology Network|Price-to-Projected Revenue Ratio BeOne Medicines (BGNE)|CKPT: Future Price to Revenue|Forward P/S Multiple ELEV (Elevation Oncology Inc.)|Forward P/S Multiple iCAD Corp ICAD|Ikena - Forward P/S Multiple|Forward Price to Sales NTBL (Notable Labs)|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple
